Skip Navigation


NDT Advance Access originally published online on October 2, 2006
Nephrology Dialysis Transplantation 2007 22(2):477-483; doi:10.1093/ndt/gfl570
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
22/2/477    most recent
gfl570v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (17)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Lok, C. E.
Right arrow Articles by Richardson, R. M. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lok, C. E.
Right arrow Articles by Richardson, R. M. A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2006]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Trisodium citrate 4%—an alternative to heparin capping of haemodialysis catheters

Charmaine E. Lok, Debra Appleton, Cynthia Bhola, Brian Khoo and Robert M. A. Richardson

University Health Network-Toronto General Hospital and the University of Toronto, Toronto, Canada

Correspondence and offprint requests to: Charmaine E. Lok, MD, Department of Medicine, Division of Nephrology, The Toronto General Hospital, 11 EN-216, 200 Elizabeth Street, Toronto, Ontario, M5G 2C4, Canada. Email: charmaine.lok{at}uhn.on.ca



  Abstract

Background. Central venous catheters (CVCs) continue to be used at a high rate for dialysis access and are frequently complicated by thrombus-related malfunction. Prophylactic locking with an anticoagulant, such as heparin, has become standard practice despite its associated risks. Trisodium citrate (citrate) 4% is an alternative catheter locking anticoagulant.

Methods. The objective was to prospectively study the clinical effectiveness, safety and cost of citrate 4% vs heparin locking by comparing rates of CVC exchanges, thrombolytic use (TPA) and access-associated hospitalizations during two study periods: heparin period (HP) (1 June 2003–15 February 2004) and Citrate Period (CP) 15 March–15 November 2004. Incident catheters evaluated did not overlap the two periods.

Results. There were 176 CVC in 121 patients (HP) and 177 CVC in 129 patients (CP). The event rates in incident CVC were: CVC exchange 2.98/1000 days (HP) vs 1.65/1000 days (CP) (P = 0.01); TPA use 5.49/1000 (HP) vs 3.3/1000 days (CP) (P = 0.002); hospitalizations 0.59/1000 days (HP) vs 0.28/1000 days (CP) (P = 0.49). There was a longer time from catheter insertion to requiring CVC exchange (P = 0.04) and TPA (P = 0.006) in the citrate compared with the heparin lock group. Citrate locking costs less than heparin locking but a formal economic analysis including indirect costs was not done.

Conclusion. Citrate 4% has equivalent or better outcomes with regards to catheter exchange, TPA use and access-related hospitalizations compared with heparin locking. It is a safe and less expensive alternative. Randomized trials comparing these anticoagulants with a control group would definitively determine the optimal haemodialysis catheter locking solution.

Keywords: citrate; haemodialysis catheters; heparin; TPA


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Nephrol Dial TransplantHome page
J. Steczko, S. R. Ash, D. E. Nivens, L. Brewer, and R. K. Winger
Microbial inactivation properties of a new antimicrobial/antithrombotic catheter lock solution (citrate/methylene blue/parabens)
Nephrol. Dial. Transplant., June 1, 2009; 24(6): 1937 - 1945.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
T. A. Takla, S. A. Zelenitsky, and L. M. Vercaigne
Effectiveness of a 30% ethanol/4% trisodium citrate locking solution in preventing biofilm formation by organisms causing haemodialysis catheter-related infections
J. Antimicrob. Chemother., November 1, 2008; 62(5): 1024 - 1026.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
G. Winnett, J. Nolan, M. Miller, and N. Ashman
Trisodium citrate 46.7% selectively and safely reduces staphylococcal catheter-related bacteraemia
Nephrol. Dial. Transplant., November 1, 2008; 23(11): 3592 - 3598.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
L. Labriola, R. Crott, and M. Jadoul
Preventing haemodialysis catheter-related bacteraemia with an antimicrobial lock solution: a meta-analysis of prospective randomized trials
Nephrol. Dial. Transplant., May 1, 2008; 23(5): 1666 - 1672.
[Abstract] [Full Text] [PDF]

Home page
 CJASNHome page
J. M. MacRae, I. Dojcinovic, O. Djurdjev, B. Jung, S. Shalansky, A. Levin, and M. Kiaii
Citrate 4% versus Heparin and the Reduction of Thrombosis Study (CHARTS)
Clin. J. Am. Soc. Nephrol., March 1, 2008; 3(2): 369 - 374.
[Abstract] [Full Text] [PDF]

Home page
 CJASNHome page
M. Allon
Current Management of Vascular Access
Clin. J. Am. Soc. Nephrol., July 1, 2007; 2(4): 786 - 800.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.